荣泰健康(603579) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 339,398,577.58, a decrease of 16.85% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 31,175,427.50, down 33.41% year-over-year[2] - Basic earnings per share for Q3 2024 was CNY 0.18, a decline of 33.33% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2024 was CNY 1,164,316,596.07, a decrease of 10.3% compared to CNY 1,298,074,815.73 in the same period of 2023[16] - Net profit for the first three quarters of 2024 was CNY 142,791,783.02, a decrease of 6.3% from CNY 152,477,626.53 in the same period of 2023[18] - Earnings per share for the first three quarters of 2024 were CNY 0.82, compared to CNY 0.87 in the same period of 2023[19] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 3,409,413,597.91, representing a slight increase of 0.72% from the end of the previous year[4] - The company's total assets amounted to RMB 3,409,413,597.91, a slight increase from RMB 3,384,898,669.64 at the end of 2023[12][13] - The total liabilities increased to CNY 1,463,677,351.76 in Q3 2024 from CNY 1,411,896,901.04 in Q3 2023, reflecting a rise of 3.7%[18] - The total equity attributable to shareholders decreased to CNY 1,941,841,141.77 in Q3 2024 from CNY 1,968,889,002.67 in Q3 2023, a decline of 1.4%[18] Cash Flow - Cash flow from operating activities for the year-to-date period showed a net outflow of CNY 17,455,309.47, a significant decline of 111.99% compared to the previous year[6] - In the first three quarters of 2024, the cash inflow from operating activities totaled ¥1,330,058,902.62, a decrease of 5.4% compared to ¥1,406,930,823.36 in the same period of 2023[20] - The net cash outflow from operating activities was ¥17,455,309.47, contrasting with a net inflow of ¥145,614,894.49 in the first three quarters of 2023[21] - The total cash outflow from operating activities was ¥1,347,514,212.09, an increase of 6.8% from ¥1,261,315,928.87 in the same period of 2023[21] Investments and Financing - Cash inflow from investment activities reached ¥2,729,995,915.95, significantly up from ¥928,811,779.15 in the previous year, marking an increase of 194.0%[21] - The net cash outflow from investment activities was ¥3,413,303,587.89, compared to ¥1,013,042,756.20 in the same period last year, indicating a substantial increase in investment spending[21] - Cash inflow from financing activities amounted to ¥378,935,396.42, up from ¥149,133,100.12 in the previous year, reflecting a growth of 153.5%[21] - The net cash flow from financing activities was ¥131,630,988.42, a recovery from a net outflow of ¥369,269,914.53 in the same period of 2023[21] Shareholder Information - The company reported a total of 12,213 common shareholders at the end of the reporting period[7] - The company plans to increase its share capital by 30% through a capital reserve transfer, increasing the total shares to 179,377,241[4] - The company has a share repurchase account holding 4,298,679 shares, representing 2.40% of total shares as of the report date[10] Legal Matters - The company reported a legal case involving a claim for economic damages of RMB 99 million, with a court ruling requiring the company to pay RMB 5.1 million[11] - The company has taken legal action in response to a lawsuit and is actively defending against the claims made[11] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 1.6%, a decrease of 0.83 percentage points year-over-year[4] - Non-recurring gains and losses for the current period amounted to CNY 5,652,581.20[5] - Research and development expenses for the first three quarters of 2024 were CNY 57,007,658.80, slightly down from CNY 59,424,399.03 in the same period of 2023[18] - The company reported a financial income of CNY 12,631,875.27 in Q3 2024, down from CNY 26,525,143.72 in Q3 2023[18] - Deferred income tax liabilities decreased to CNY 16,580,653.93 in Q3 2024 from CNY 19,550,558.11 in Q3 2023, a reduction of 15.4%[18] - The company's cash and cash equivalents decreased to RMB 807,660,357.48 from RMB 1,383,940,623.85, representing a decline of approximately 41.5%[12]